PegIntron Increases Relapse-Free Survival In Stage III Melanoma, Schering Says
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. approval as adjuvant therapy for melanoma has been delayed by ODAC data requests, postponed meeting.